SGLT2 inhibition, high-density lipoprotein cholesterol and aortic aneurysm: A drug-target Mendelian randomization study
Nutrition, Metabolism and Cardiovascular Diseases · 2026-08 · 36 (8) · 104701
DOI: 10.1016/j.numecd.2026.104701 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nutrition, Metabolism and Cardiovascular Diseases, 2026-08. Verfasst von Zheng-Qi Song und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, 325000, Nanbaixiang, Wenzhou, Zhejiang, China; The First Clini…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Sodium-Glucose Transporter 2, Cholesterol, HDL. Die Arbeit nennt 40 Literaturangaben. Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
BACKGROUND AND AIM The causal effect of sodium-glucose cotransporter 2 (SGLT2) inhibition on aortic aneurysm (AA), as well as the underlying lipid metabolism, remain largely unexplored. METHODS AND RESULTS We extracted genetic variants within the cis-region of the SLC5A2 gene from the genome-wide association study of hemoglobin A1c (HbA1c) to proxy the effects of SGLT2 inhibition. Two-sample Mendelian randomization (MR) was subsequently performed to evaluate the causal effect of SGLT2 inhibition on type 2 diabetes mellitus (T2DM, serving as a positive control) and AA. Two-step mediation MR was further implemented to elucidate the potential mediating role of lipid metabolism in the pathway linking SGLT2 inhibition to AA. We found genetically predicted SGLT2 inhibition (per 1 SD decrease in HbA1c) was associated with reduced risk of T2DM (OR: 0.62, 95% CI: 0.45, 0.86, PFDR = 0.008) and AA (OR: 0.84, 95% CI: 0.77, 0.92, PFDR = 7.36 × 10-4). Subgroup analysis indicated that SGLT2 inhibition could lower the incidence of abdominal AA (OR: 0.90, 95% CI: 0.82, 0.99, PFDR = 0.024) and thoracic AA (OR: 0.87, 95% CI: 0.78, 0.98, PFDR = 0.024). Mediation analysis suggested that high-density lipoprotein cholesterol (HDL-C) mediated the effect of SGLT2 inhibition on AA and abdominal AA, with a mediated proportion of 3.55% (95% CI: 1.38%, 5.72%, P = 0.001) and 6.14% (95% CI: 2.63%, 9.64%, P = 5.60 × 10-4), respectively. CONCLUSION Our study demonstrated that HDL-C could partially mediate the protective effect of SGLT2 inhibition on AA, particularly on abdominal AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, 325000, Nanbaixiang, Wenzhou, Zhejiang, China; The First Clinical Medical College, Wenzhou Medical University, 325000, Chashan, Wenz…
- Department of Cardiology, The First People's Hospital of JinZhong, Yuci, China.
- The First Clinical Medical College, Wenzhou Medical University, 325000, Chashan, Wenzhou, Zhejiang, China.
- Department of Rheumatology and Immunology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China. Electronic address: xiuxiuchen@wmu.edu.cn.
- Department of Cardiology, The First Affiliated Hospital of Wenzhou Medical University, 325000, Nanbaixiang, Wenzhou, Zhejiang, China. Electronic address: chenyihe@wmu.edu.cn.
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Song, Z. Q., Pei, Y. Z., Wu, S. K., Chen, X. X., & Chen, Y. H. (2026). SGLT2 inhibition, high-density lipoprotein cholesterol and aortic aneurysm: A drug-target Mendelian randomization study. Nutrition, Metabolism and Cardiovascular Diseases, 36(8), 104701. https://doi.org/10.1016/j.numecd.2026.104701
Vancouver
Song ZQ, Pei YZ, Wu SK, Chen XX, Chen YH. SGLT2 inhibition, high-density lipoprotein cholesterol and aortic aneurysm: A drug-target Mendelian randomization study. Nutrition, Metabolism and Cardiovascular Diseases. 2026;36(8):104701. doi:10.1016/j.numecd.2026.104701
BibTeX
@article{Song2026,
author = {Song, Zheng-Qi and Pei, Yan-Zhen and Wu, Sheng-Ke and Chen, Xiu-Xiu and Chen, Yi-He},
title = {SGLT2 inhibition, high-density lipoprotein cholesterol and aortic aneurysm: A drug-target Mendelian randomization study},
journal = {Nutrition, Metabolism and Cardiovascular Diseases},
year = {2026},
volume = {36},
number = {8},
pages = {104701},
doi = {10.1016/j.numecd.2026.104701}
}
EUVIMED